
The outcome of a formulary interchange from zzso to zzso for the zzso of zzso for zzso receiving zzso chemotherapy was zzso The pharmacy department at the James Graham Brown Cancer Center of the University of Louisville Hospital implemented a therapeutic interchange program by following the Joint Commission on Accreditation of Healthcare zzso performance methodology, incorporating four key zzso plan, do, check, and zzso After the pharmacy and zzso committee agreed that zzso and zzso are zzso zzso the pharmacy initiated the zzso with a commitment to collect outcomes data to analyze the impact of the program on patient zzso zzso criteria included patient age of zzso or zzso 18 years, the presence of solid tumors or lymphoma, and current treatment with traditional zzso Patient demographics and zzso data were collected for 31 patients receiving zzso and 20 patients receiving zzso from August 2000 to July zzso Absolute zzso counts zzso were measured before initiating and after zzso zzso zzso The majority zzso of all growth factor use was initiated within one to four days of the last chemotherapy zzso No appreciable difference was found between agents for median zzso at any measured time zzso The majority of patients exceeded the target zzso of 1500 zzso at the time of growth factor zzso There were no significant differences in the number of patients that had adverse effects or in the number of cycles resulting in an adverse event between zzso zzso demonstrated a zzso cost savings over zzso zzso versus zzso zzso The formulary switch from zzso to zzso resulted in a significant cost savings for the institution without increasing zzso of adverse effects and negative outcomes associated with growth factor zzso 

